IADR Abstract Archives
Anti-Sensitivity Efficacy of Bioavailable Stannous Fluoride Dentifrice vs. Negative Control.
Objectives: To evaluate the dentinal hypersensitivity relief benefit of a new desensitizing dentifrice with bioavailable SnF2 as compared to the negative control after three days, 3 and 4 weeks of product use.
Methods: This study was a randomized, parallel group, controlled, 4-week clinical trial. Subjects with dentinal hypersensitivity on 2 teeth (Yeaple Probe 10-20g) were enrolled and randomized to one of the treatment groups: a 0.454% stannous fluoride dentifrice (Crest® Gum and Sensitivity), or a negative control (Crest® Cavity Protection). Subjects in both groups, used their test product twice daily at home, for 4 weeks according to the manufacture instructions. Tactile sensitivity assessments were performed using a standard calibrated Yeaple probe at baseline, three days, 3 and 4 weeks after product use. Treatments were compared using ANOVA statistical analysis.
Results: Eighty subjects were randomized to treatment and 77 subjects completed the study with a mean age of 41 years. Treatment groups were balanced on Baseline Yeaple scores, age and gender (p≥0.2541). Relative to the control, the bioavailable stannous fluoride dentifrice demonstrated significant improvement in mean Yeaple scores (p<0.0001) by 75.2% at Day 3, 91% at week 3 and 135% at week 4. Ninety-seven percent of subjects using the stannous fluoride dentifrice had relief from tactile sensitivity at Week 4 compared to only 28% in the control group (p<0.0001). The number of subjects showing improvement was significantly greater for the stannous fluoride dentifrice group versus the control group at all 3 timepoints. No adverse events were reported with either dentifrice.
Conclusions: The new, desensitizing dentifrice with bioavailable stannous fluoride provided greater short-term and long-term dentinal hypersensitivity relief when compared to the negative control.
Methods: This study was a randomized, parallel group, controlled, 4-week clinical trial. Subjects with dentinal hypersensitivity on 2 teeth (Yeaple Probe 10-20g) were enrolled and randomized to one of the treatment groups: a 0.454% stannous fluoride dentifrice (Crest® Gum and Sensitivity), or a negative control (Crest® Cavity Protection). Subjects in both groups, used their test product twice daily at home, for 4 weeks according to the manufacture instructions. Tactile sensitivity assessments were performed using a standard calibrated Yeaple probe at baseline, three days, 3 and 4 weeks after product use. Treatments were compared using ANOVA statistical analysis.
Results: Eighty subjects were randomized to treatment and 77 subjects completed the study with a mean age of 41 years. Treatment groups were balanced on Baseline Yeaple scores, age and gender (p≥0.2541). Relative to the control, the bioavailable stannous fluoride dentifrice demonstrated significant improvement in mean Yeaple scores (p<0.0001) by 75.2% at Day 3, 91% at week 3 and 135% at week 4. Ninety-seven percent of subjects using the stannous fluoride dentifrice had relief from tactile sensitivity at Week 4 compared to only 28% in the control group (p<0.0001). The number of subjects showing improvement was significantly greater for the stannous fluoride dentifrice group versus the control group at all 3 timepoints. No adverse events were reported with either dentifrice.
Conclusions: The new, desensitizing dentifrice with bioavailable stannous fluoride provided greater short-term and long-term dentinal hypersensitivity relief when compared to the negative control.